人工光和神经退行:光污染是否会影响阿尔茨海默病的发展?
Julia Karska1, Szymon Kowalski2, Anna Gładka3
1Department of Psychiatry, Wrocław Medical University, Pasteura 10, 50-367, Wrocław, Poland. julia.karska@student.umw.edu.pl.
GeroScience
|September 21, 2023
概括
光污染可能会通过破坏昼夜节律并导致神经退行导致阿尔茨海默病恶化. 需要进一步的研究才能充分理解人工光与大脑健康之间的复杂关系.
科学领域:
- 环境科学 环境科学
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 阿尔茨海默病的发病因子仍然不完全理解.
- 夜间的人工光 (ALAN) 带来了重大的环境和健康风险.
- 众所周知,ALAN会破坏昼夜节律.
研究的目的:
- 探索光污染和阿尔茨海默病之间的潜在相互关系.
- 调查ALAN对昼夜节律的干扰如何可能导致神经退行.
主要方法:
- 关于光污染和阿尔茨海默病的现有科学文献的审查.
- 对昼夜失调的生理影响的分析.
主要成果:
- 不适当的照明条件会扰乱昼夜节律,影响睡眠和清醒周期,基因表达,神经元功能和肠道微生物群.
- 这些干扰与神经退行过程有关.
- 现有的研究表明,光污染和阿尔茨海默病之间存在复杂的相关性.
结论:
- 由于光污染导致的循环节律障碍可能是导致阿尔茨海默病的一个因素.
- 进一步的研究对于阐明将光污染与神经退行和阿尔茨海默病联系在一起的机制至关重要.
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Photoreceptors and Visual Pathways
6.1K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.1K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


